---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-056909"
form_type: "8-K"
ticker: "NKTR"
cik: "0000906709"
company_name: "NEKTAR THERAPEUTICS"
filed_at: "2025-06-24T23:59:59+00:00"
generated_at: "2026-05-18T23:12:11.947279+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Nektar’s rezpegaldesleukin meets primary & key secondary endpoints in Phase 2b atopic dermatitis trial

## Summary
- REZOLVE-AD met primary endpoint: mean EASI improvement from baseline at week 16 for all three rezpegaldesleukin dose arms vs placebo (p<0.001).
- EASI-75 achieved by 42-46% of rezpegaldesleukin patients vs 17% placebo; high dose also significant on EASI-90 (25% vs 9%).
- Itch NRS (≥4-point reduction) 42% high dose, 35% middle dose vs 16% placebo; vIGA-AD 0/1 significant for q2w arms.
- Safety profile consistent: injection site reactions (69.7%) mostly mild/moderate; no increased conjunctivitis, oral ulcers, or infections.
- On-target Treg proliferation up to 6-fold; full 52-week data expected early 2026, alopecia areata top-line Q4 2025.

## SEC filing metadata
- accession: 0001213900-25-056909
- form_type: 8-K
- ticker: NKTR
- cik: 0000906709
- company_name: NEKTAR THERAPEUTICS
- filed_at: 2025-06-24T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/906709/000121390025056909/0001213900-25-056909-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/906709/000121390025056909/ea0246672-8k_nektar.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-056909
- JSON: https://secwatch.observer/filing/0001213900-25-056909.json
- Plain text: https://secwatch.observer/filing/0001213900-25-056909.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.